Evotec SE (EVO) Stock Forecast, Price Target & Predictions
EVO Stock Forecast
Evotec SE stock forecast is as follows: an average price target of $8.00 (represents a 81.82% upside from EVO’s last price of $4.40) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.
EVO Price Target
The average price target for Evotec SE (EVO) is $8.00 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $8.00 to $8.00. This represents a potential 81.82% upside from EVO's last price of $4.40.
EVO Analyst Ratings
According to 7 Wall Street analysts, Evotec SE's rating consensus is 'Buy'. The analyst rating breakdown for EVO stock is 0 'Strong Buy' (0.00%), 3 'Buy' (42.86%), 3 'Hold' (42.86%), 1 'Sell' (14.29%), and 0 'Strong Sell' (0.00%).
Evotec SE Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 15, 2024 | Douglas Tsao | H.C. Wainwright | $8.00 | $3.22 | 148.45% | 81.82% |
| Apr 25, 2024 | Douglas Tsao | H.C. Wainwright | $11.00 | $5.23 | 110.33% | 150.00% |
| Dec 09, 2022 | - | H.C. Wainwright | $12.00 | $8.38 | 43.20% | 172.73% |
The latest Evotec SE stock forecast, released on Aug 15, 2024 by Douglas Tsao from H.C. Wainwright, set a price target of $8.00, which represents a 148.45% increase from the stock price at the time of the forecast ($3.22), and a 81.82% increase from EVO last price ($4.40).
Evotec SE Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 2 |
| Avg Price Target | - | $8.00 | $9.50 |
| Last Closing Price | $4.40 | $4.40 | $4.40 |
| Upside/Downside | -100.00% | 81.82% | 115.91% |
In the current month, the average price target of Evotec SE stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Evotec SE's last price of $4.40. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 07, 2024 | Jefferies | - | Hold | Downgrade |
| Aug 15, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 08, 2024 | Deutsche Bank | Hold | Sell | Downgrade |
| Aug 07, 2024 | Oddo BHF | - | Neutral | Downgrade |
| Jul 29, 2024 | Morgan Stanley | Overweight | Equal-Weight | Downgrade |
| Jul 11, 2024 | Deutsche Bank | Buy | Hold | Downgrade |
| Jun 28, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Apr 25, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Apr 12, 2024 | Deutsche Bank | Hold | Buy | Upgrade |
| Aug 31, 2023 | Citigroup | Buy | Buy | Hold |
Evotec SE's last stock rating was published by Jefferies on Oct 07, 2024. The company Downgrade its EVO rating from "null" to "Hold".
Evotec SE Financial Forecast
Evotec SE Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $240.69M | $173.88M | $172.20M | $164.67M | $187.07M | $133.09M | $140.51M | $129.43M | $111.59M | $119.40M | $125.08M | $114.27M | $103.24M |
| Avg Forecast | $250.38M | $244.09M | $271.24M | $270.91M | $240.84M | $209.11M | $220.08M | $210.52M | $210.06M | $190.79M | $198.27M | $217.53M | $178.45M | $178.15M | $163.99M | $173.14M | $182.96M | $137.76M | $137.46M | $128.42M | $146.42M | $126.17M | $119.65M | $114.04M | $103.15M |
| High Forecast | $250.38M | $244.09M | $271.24M | $270.91M | $240.84M | $212.98M | $227.59M | $210.52M | $222.93M | $195.72M | $198.27M | $217.53M | $178.45M | $178.15M | $163.99M | $173.14M | $182.96M | $137.76M | $137.46M | $128.42M | $146.42M | $126.17M | $119.65M | $114.04M | $103.15M |
| Low Forecast | $250.38M | $244.09M | $271.24M | $270.91M | $240.84M | $205.24M | $212.58M | $210.52M | $197.17M | $185.87M | $198.27M | $217.53M | $178.45M | $178.15M | $163.99M | $173.14M | $182.96M | $137.76M | $137.46M | $128.42M | $146.42M | $126.17M | $119.65M | $114.04M | $103.15M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.35% | 0.98% | 1.05% | 0.95% | 1.02% | 0.97% | 1.02% | 1.01% | 0.76% | 0.95% | 1.05% | 1.00% | 1.00% |
Evotec SE's average Quarter revenue forecast for Mar 23 based on 1 analysts is $217.53M, with a low forecast of $217.53M, and a high forecast of $217.53M. EVO's average Quarter revenue forecast represents a -9.62% decrease compared to the company's last Quarter revenue of $240.69M (Dec 22).
Evotec SE EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $35.65M | $-14.16M | $-6.50M | $60.31M | $-14.82M | $56.75M | $6.46M | $8.87M | $-4.41M | $26.77M | $16.01M | $26.65M | $3.77M |
| Avg Forecast | $37.05M | $36.12M | $40.13M | $40.08M | $35.64M | $30.94M | $32.56M | $31.15M | $31.08M | $28.23M | $29.34M | $32.19M | $26.40M | $26.36M | $24.26M | $-75.35M | $27.07M | $20.38M | $20.34M | $19.00M | $21.66M | $18.67M | $17.70M | $16.87M | $15.26M |
| High Forecast | $37.05M | $36.12M | $40.13M | $40.08M | $35.64M | $31.51M | $33.67M | $31.15M | $32.99M | $28.96M | $29.34M | $32.19M | $26.40M | $26.36M | $24.26M | $-60.28M | $27.07M | $20.38M | $20.34M | $19.00M | $21.66M | $18.67M | $17.70M | $16.87M | $15.26M |
| Low Forecast | $37.05M | $36.12M | $40.13M | $40.08M | $35.64M | $30.37M | $31.45M | $31.15M | $29.17M | $27.50M | $29.34M | $32.19M | $26.40M | $26.36M | $24.26M | $-90.42M | $27.07M | $20.38M | $20.34M | $19.00M | $21.66M | $18.67M | $17.70M | $16.87M | $15.26M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.35% | -0.54% | -0.27% | -0.80% | -0.55% | 2.78% | 0.32% | 0.47% | -0.20% | 1.43% | 0.90% | 1.58% | 0.25% |
1 analysts predict EVO's average Quarter EBITDA for Mar 23 to be $32.19M, with a high of $32.19M and a low of $32.19M. This is -9.72% lower than Evotec SE's previous annual EBITDA (Dec 22) of $35.65M.
Evotec SE Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $-27.20M | $-47.27M | $-27.94M | $-73.24M | $-31.48M | $52.70M | $403.00K | $-1.41M | $-9.82M | $22.23M | $8.36M | $19.05M | $-2.39M |
| Avg Forecast | $1.79M | $1.79M | $5.36M | $1.79M | $-5.55M | $-9.52M | $-6.32M | $-4.22M | $-4.83M | $-4.83M | $-9.83M | $14.33M | $-1.33M | $-15.02M | $5.49M | $-85.45M | $311.66M | $2.68M | $2.58M | $451.19K | $8.66M | $4.26M | $7.02M | $9.08M | $6.78M |
| High Forecast | $1.79M | $1.79M | $5.36M | $1.79M | $-5.55M | $-4.23M | $-6.32M | $-4.22M | $1.61M | $-4.83M | $-9.83M | $14.33M | $-1.33M | $-15.02M | $5.49M | $-68.36M | $311.66M | $2.68M | $2.58M | $451.19K | $8.66M | $4.26M | $7.02M | $9.08M | $6.78M |
| Low Forecast | $1.79M | $1.79M | $5.36M | $1.79M | $-5.55M | $-14.82M | $-6.32M | $-4.22M | $-11.28M | $-4.83M | $-9.83M | $14.33M | $-1.33M | $-15.02M | $5.49M | $-102.54M | $311.66M | $2.68M | $2.58M | $451.19K | $8.66M | $4.26M | $7.02M | $9.08M | $6.78M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 20.49% | 3.15% | -5.09% | 0.86% | -0.10% | 19.63% | 0.16% | -3.13% | -1.13% | 5.21% | 1.19% | 2.10% | -0.35% |
Evotec SE's average Quarter net income forecast for Dec 21 is $311.66M, with a range of $311.66M to $311.66M. EVO's average Quarter net income forecast represents a 491.35% increase compared to the company's last Quarter net income of $52.70M (Mar 21).
Evotec SE SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $46.33M | $42.46M | $35.83M | $31.57M | $34.41M | $21.19M | $19.11M | $21.60M | $19.28M | $17.25M | $20.32M | $16.32M | $15.14M |
| Avg Forecast | $45.01M | $43.88M | $48.76M | $48.70M | $43.29M | $37.59M | $39.56M | $37.84M | $37.76M | $34.30M | $35.64M | $39.10M | $32.08M | $32.02M | $29.48M | $36.83M | $32.89M | $24.76M | $24.71M | $23.08M | $26.32M | $22.68M | $21.51M | $20.50M | $18.54M |
| High Forecast | $45.01M | $43.88M | $48.76M | $48.70M | $43.29M | $38.28M | $40.91M | $37.84M | $40.07M | $35.18M | $35.64M | $39.10M | $32.08M | $32.02M | $29.48M | $44.19M | $32.89M | $24.76M | $24.71M | $23.08M | $26.32M | $22.68M | $21.51M | $20.50M | $18.54M |
| Low Forecast | $45.01M | $43.88M | $48.76M | $48.70M | $43.29M | $36.89M | $38.21M | $37.84M | $35.44M | $33.41M | $35.64M | $39.10M | $32.08M | $32.02M | $29.48M | $29.46M | $32.89M | $24.76M | $24.71M | $23.08M | $26.32M | $22.68M | $21.51M | $20.50M | $18.54M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.44% | 1.33% | 1.22% | 0.86% | 1.05% | 0.86% | 0.77% | 0.94% | 0.73% | 0.76% | 0.94% | 0.80% | 0.82% |
Evotec SE's average Quarter SG&A projection for Mar 23 is $39.10M, based on 1 Wall Street analysts, with a range of $39.10M to $39.10M. The forecast indicates a -15.61% fall compared to EVO last annual SG&A of $46.33M (Dec 22).
Evotec SE EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $-0.08 | $-0.13 | $-0.08 | $-0.21 | $-0.09 | $0.16 | - | $-0.01 | $-0.04 | $0.06 | $0.03 | $0.07 | $-0.01 |
| Avg Forecast | $0.01 | $0.01 | $0.03 | $0.01 | $-0.03 | $-0.05 | $-0.04 | $-0.02 | $-0.03 | $-0.03 | $-0.06 | $0.08 | $-0.01 | $-0.08 | $0.03 | $0.06 | $1.76 | $0.02 | $0.01 | - | $0.05 | $0.02 | $0.04 | $0.05 | $0.04 |
| High Forecast | $0.01 | $0.01 | $0.03 | $0.01 | $-0.03 | $-0.02 | $-0.04 | $-0.02 | $0.01 | $-0.03 | $-0.06 | $0.08 | $-0.01 | $-0.08 | $0.03 | $0.06 | $1.76 | $0.02 | $0.01 | - | $0.05 | $0.02 | $0.04 | $0.05 | $0.04 |
| Low Forecast | $0.01 | $0.01 | $0.03 | $0.01 | $-0.03 | $-0.08 | $-0.04 | $-0.02 | $-0.06 | $-0.03 | $-0.06 | $0.08 | $-0.01 | $-0.08 | $0.03 | $0.06 | $1.76 | $0.02 | $0.01 | - | $0.05 | $0.02 | $0.04 | $0.05 | $0.04 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 10.29% | 1.53% | -2.56% | -3.56% | -0.05% | 10.57% | 0.09% | -1.96% | -0.72% | 2.29% | 0.70% | 1.27% | -0.26% |
According to 1 Wall Street analysts, Evotec SE's projected average Quarter EPS for Dec 21 is $1.76, with a low estimate of $1.76 and a high estimate of $1.76. This represents a 998.59% increase compared to EVO previous annual EPS of $0.16 (Mar 21).
Evotec SE Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PCRX | Pacira BioSciences | $16.45 | $40.00 | 143.16% | Hold |
| EVO | Evotec SE | $4.40 | $8.00 | 81.82% | Buy |
| ANIP | ANI Pharmaceuticals | $56.01 | $79.00 | 41.05% | Buy |
| COLL | Collegium Pharmaceutical | $32.72 | $41.50 | 26.83% | Buy |
| NBIX | Neurocrine Biosciences | $120.53 | $147.70 | 22.54% | Buy |
| PBH | Prestige Consumer Healthcare | $73.79 | $82.00 | 11.13% | Buy |
| SUPN | Supernus Pharmaceuticals | $34.70 | $38.00 | 9.51% | Buy |
| DCPH | Deciphera Pharmaceuticals | $25.59 | $26.32 | 2.85% | Hold |
| PAHC | Phibro Animal Health | $22.37 | $18.67 | -16.54% | Buy |
EVO Forecast FAQ
Is Evotec SE a good buy?
Yes, according to 7 Wall Street analysts, Evotec SE (EVO) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 42.86% of EVO's total ratings.
What is EVO's price target?
Evotec SE (EVO) average price target is $8 with a range of $8 to $8, implying a 81.82% from its last price of $4.4. The data is based on 7 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Evotec SE stock go up soon?
According to Wall Street analysts' prediction for EVO stock, the company can go up by 81.82% (from the last price of $4.4 to the average price target of $8), up by 81.82% based on the highest stock price target, and up by 81.82% based on the lowest stock price target.
Can Evotec SE stock reach $7?
EVO's average twelve months analyst stock price target of $8 supports the claim that Evotec SE can reach $7 in the near future.
What are Evotec SE's analysts' financial forecasts?
Evotec SE's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $880.56M (high $891.93M, low $869.18M), average EBITDA is $130.29M (high $131.97M, low $128.61M), average net income is $-25.607M (high $-20.315M, low $-30.899M), average SG&A $158.28M (high $160.33M, low $156.24M), and average EPS is $-0.144 (high $-0.115, low $-0.174). EVO's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $1.04B (high $1.04B, low $1.04B), average EBITDA is $153.38M (high $153.38M, low $153.38M), average net income is $10.73M (high $10.73M, low $10.73M), average SG&A $186.34M (high $186.34M, low $186.34M), and average EPS is $0.0605 (high $0.0605, low $0.0605).
Did the EVO's actual financial results beat the analysts' financial forecasts?
Based on Evotec SE's last annual report (Dec 2022), the company's revenue was $751.45M, beating the average analysts forecast of $693.72M by 8.32%. Apple's EBITDA was $94.15M, beating the average prediction of $1.68M by 5503.49%. The company's net income was $-176M, beating the average estimation of $-96.314M by 82.38%. Apple's SG&A was $156.19M, beating the average forecast of $130.4M by 19.77%. Lastly, the company's EPS was $-0.5, beating the average prediction of $-0.00223 by 22275.87%. In terms of the last quarterly report (Dec 2022), Evotec SE's revenue was $240.69M, beating the average analysts' forecast of $178.45M by 34.88%. The company's EBITDA was $35.65M, beating the average prediction of $26.4M by 35.02%. Evotec SE's net income was $-27.201M, beating the average estimation of $-1.327M by 1949.30%. The company's SG&A was $46.33M, beating the average forecast of $32.08M by 44.44%. Lastly, the company's EPS was $-0.077, beating the average prediction of $-0.00749 by 928.56%